Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,362 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk evaluation of coronary heart disease and cerebrovascular disease by the Japan Atherosclerosis Society Guidelines 2002 using the cohort of the Holicos-PAT study.
Koizumi J, Shimizu M, Miyamoto S, Takeda R, Ohka T, Kanaya H, Uno Y, Ueda K, Takegoshi T, Wakasugi T, Ohta M, Sumitani T, Kametani T, Watanabe A, Fujita H, Hifumi S, Origasa H, Mabuchi H. Koizumi J, et al. Among authors: miyamoto s. J Atheroscler Thromb. 2005;12(1):48-52. doi: 10.5551/jat.12.48. J Atheroscler Thromb. 2005. PMID: 15725696 Free article.
Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan.
Ogawa A, Mori E, Minematsu K, Taki W, Takahashi A, Nemoto S, Miyamoto S, Sasaki M, Inoue T; MELT Japan Study Group. Ogawa A, et al. Among authors: miyamoto s. Stroke. 2007 Oct;38(10):2633-9. doi: 10.1161/STROKEAHA.107.488551. Epub 2007 Aug 16. Stroke. 2007. PMID: 17702958 Clinical Trial.
One-year atherothrombotic vascular events rates in outpatients with recent non-cardioembolic ischemic stroke: the EVEREST (Effective Vascular Event REduction after STroke) registry.
Suzuki N, Sato M, Houkin K, Terayama Y, Uchiyama S, Daida H, Shigematsu H, Goto S, Tanaka K, Origasa H, Miyamoto S, Minematsu K, Matsumoto M, Okada Y. Suzuki N, et al. Among authors: miyamoto s. J Stroke Cerebrovasc Dis. 2012 May;21(4):245-53. doi: 10.1016/j.jstrokecerebrovasdis.2012.01.010. Epub 2012 Feb 24. J Stroke Cerebrovasc Dis. 2012. PMID: 22365283
Guidelines for the intravenous application of recombinant tissue-type plasminogen activator (alteplase), the second edition, October 2012: a guideline from the Japan Stroke Society.
Minematsu K, Toyoda K, Hirano T, Kimura K, Kondo R, Mori E, Nakagawara J, Sakai N, Shiokawa Y, Tanahashi N, Yasaka M, Katayama Y, Miyamoto S, Ogawa A, Sasaki M, Suga S, Yamaguchi T; Japan Stroke Society. Minematsu K, et al. Among authors: miyamoto s. J Stroke Cerebrovasc Dis. 2013 Jul;22(5):571-600. doi: 10.1016/j.jstrokecerebrovasdis.2013.04.001. Epub 2013 May 31. J Stroke Cerebrovasc Dis. 2013. PMID: 23727456 Review.
Present profiles of novel anticoagulant use in Japanese patients with atrial fibrillation: insights from the Rivaroxaban Postmarketing Surveillance Registry.
Ogawa S, Ikeda T, Kitazono T, Nakagawara J, Minematsu K, Miyamoto S, Murakawa Y, Iekushi K, Yamanaka S, Yamada T, Inuyama L; Rivaroxaban PostMarketing Surveillance Registry Investigators. Ogawa S, et al. Among authors: miyamoto s. J Stroke Cerebrovasc Dis. 2014 Nov-Dec;23(10):2520-2526. doi: 10.1016/j.jstrokecerebrovasdis.2014.03.006. Epub 2014 Sep 20. J Stroke Cerebrovasc Dis. 2014. PMID: 25245483
3,362 results